Essential Thrombocythemia (ET) Clinical Trials

Essential Thrombocythemia is a myeloproliferative neoplasm characterized by sustained elevated platelet counts (typically greater than 450,000 per microliter) resulting from clonal proliferation of megakaryocytes in the bone marrow. The disease occurs in three major genetic subtypes: JAK2-positive (50-60%), CALR-positive (20-30%), and MPL-positive (5-10%), with the remaining cases being 'triple-negative.' These mutations drive uncontrolled megakaryocyte proliferation independent of normal growth signals. The elevated platelet count paradoxically increases both thrombotic risk (blood clots) and hemorrhagic risk (bleeding), due to both quantitative increases in platelets and qualitative functional abnormalities.

The most common symptoms of Essential Thrombocythemia include Fatigue and weakness, Headaches and dizziness, Chest discomfort or pain, Numbness, tingling, or burning in hands and feet, Bleeding or bruising easily, among others. About 1 new case per 100,000 people each year, with an estimated 30 to 60 per 100,000 living with it (NORD); average age at diagnosis is in the mid-fifties. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Essential Thrombocythemia from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Research in Essential Thrombocythemia is evolving toward personalized treatment strategies that account for your specific genetic makeup and risk profile. Clinical trials are testing targeted JAK inhibitors, HDAC inhibitors, and innovative agents designed to reduce platelet production while preserving quality of life and keeping side effects manageable.

Yes. As of October 21, 2026, 2 FDA-approved medicines have a current label that names Essential Thrombocythemia: Besremi (ropeginterferon alfa-2b-njft), first approved in 2021; and Agrylin (anagrelide hydrochloride). Corticosteroids and immune globulins count once each.

Essential Thrombocythemia arises from acquired (somatic) genetic changes in the affected cells, commonly involving JAK2, CALR and MPL, rather than from an inherited variant. Acquired driver mutations in blood-forming cells (JAK2 V617F most common, then CALR, then MPL) are tested on peripheral blood; rare familial cases are autosomal dominant. About 1 new case per 100,000 people each year, with an estimated 30 to 60 per 100,000 living with it (NORD); average age at diagnosis is in the mid-fifties.

For Essential Thrombocythemia the genetic testing that matters is usually of the tumor or affected blood cells rather than inherited DNA, looking for JAK2, CALR and MPL. Acquired driver mutations in blood-forming cells (JAK2 V617F most common, then CALR, then MPL) are tested on peripheral blood; rare familial cases are autosomal dominant.

Those results guide treatment choice and are often the entry requirement for targeted-therapy trials, so ask whether the biopsy was sent for molecular testing and request the report. The Genetic Testing section of this page lists laboratories in the NIH Genetic Testing Registry.

Eligibility for Essential Thrombocythemia clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Essential Thrombocythemia clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.